Related Experiment Video
Updated: Nov 23, 2025
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies
Chunling Zhou1, Xiaoxin Li1, Aiping He1
1Liaoning Institute for Drug Control, Liaoning Inspection, Examination & Certification Centre, Shenyang 110035, China.
Abstract:
VS-5584 is a small-molecular compound that showed equivalent activity against mTOR and all class I PI3K isoforms and demonstrated preclinical activity in diverse cancer cell lines and xenograft tumor model, and rational combination of VS-5584 and other target therapies achieved promising outcomes in oncology. In the present study, we established and validated a simple and sensitive UPLC-MS/MS method for the determination of VS-5584 in plasma samples. VS-5584 was separated via an Acquity UPLC BEH C18 column, with a mobile phase composed of acetonitrile and 0.2% formic acid in water (40 : 60). The calibration curve displayed a good linearity in the range of 1.0-1000 ng/mL, with satisfactory accuracy (-13.6% < RE% < 8.8%) and precision (CV%, less than 9.2%). The validated method was then applied to a pharmacokinetic study in rats. After administration of 10 mg/kg, VS-5584 was absorbed quickly and reached a peak concentration of 473.2 ± 72.0 ng/mL after 20 min. The established method allows for the quantification of VS-5584 in rat plasma in detail and can be utilized to successfully describe the pharmacokinetic profile of VS-5584.
Insights
A new UPLC-MS/MS method accurately measures VS-5584, a promising anti-cancer compound, in rat plasma. This validated assay enables detailed pharmacokinetic studies for VS-5584 drug development.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Oncology
Background:
- VS-5584 is a small-molecule inhibitor targeting mTOR and PI3K, showing preclinical anti-cancer activity.
- Combination therapies involving VS-5584 have demonstrated promising oncological outcomes.
Purpose of the Study:
- To develop and validate a sensitive Ultra-Performance Liquid Chromatography-tandem Mass Spectrometry (UPLC-MS/MS) method for quantifying VS-5584 in biological matrices.
- To apply the validated method to analyze the pharmacokinetic profile of VS-5584 in rats.
Main Methods:
- VS-5584 separation using an Acquity UPLC BEH C18 column.
- A mobile phase consisting of acetonitrile and 0.2% formic acid in water (40:60).
- Method validation for linearity, accuracy, and precision within the 1.0-1000 ng/mL range.
Main Results:
- The UPLC-MS/MS method demonstrated good linearity, accuracy (RE% between -13.6% and 8.8%), and precision (CV% < 9.2%).
- The validated method was successfully applied to a pharmacokinetic study in rats.
- VS-5584 exhibited rapid absorption, reaching a peak plasma concentration of 473.2 ± 72.0 ng/mL at 20 minutes post-10 mg/kg administration.
Conclusions:
- A simple, sensitive, and validated UPLC-MS/MS method for VS-5584 determination in rat plasma was established.
- The method provides detailed quantification essential for understanding VS-5584 pharmacokinetics.
- This validated assay supports further preclinical and clinical development of VS-5584.
More Related Videos
07:34Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS
Published on: March 14, 2013
11:00Untargeted Metabolomics from Biological Sources Using Ultraperformance Liquid Chromatography-High Resolution Mass Spectrometry UPLC-HRMS
Published on: May 20, 2013